BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); • Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation). BERKELEY, Calif., and VANCOUVER, British Columbia, November 12, 2019 — BriaCell …

BriaCell Announces Voting Results of the Special Meeting of Shareholders

BERKELEY, Calif., and VANCOUVER, British Columbia, October 24, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the special meeting (the “Meeting“) of the holders of common shares (the “Common Shares“) …

BriaCell Announces Closing of Non-Brokered Private Placement of $568,444

BERKELEY, Calif., and VANCOUVER, British Columbia, October 15, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, …

BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

BERKELEY, Calif., and VANCOUVER, British Columbia, October 8, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed on SEDAR an amendment to its management information circular dated September 23, 2019 (the “Circular”) to amend the maximum …

BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

• Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. • Cancer blocks the immune system preventing it from fighting and destroying cancer cells. Bria-IMT™ activates the immune system to fight and eliminate …

BriaCell Therapeutics Corp. to Clarify Record Date

BERKELEY, Calif., and VANCOUVER, British Columbia, October 1, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22, 2019 (the “Meeting”). The Company would like …

Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

BERKELEY, Calif., and VANCOUVER, British Columbia, October 1, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer …

BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals

BERKELEY, Calif., and VANCOUVER, British Columbia, September 25, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. Additionally, Dr. Bill Williams, BriaCell’s President …

BriaCell Announces Private Placement of up to $600,000

BERKELEY, Calif., and VANCOUVER, British Columbia, September 20, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company …

BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress. Publicly-traded securities of BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) will remain halted for the duration of CEO Dr. Williams’ presentation. • Robust responder experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland …